Chen Xiaohui, Jia Fan, Li Yongzhou, Deng Yongyan, Huang Yue, Liu Weifeng, Jin Qiao, Ji Jian
MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027, Zhejiang Province, PR China.
Department of Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, Zhejiang Province, PR China.
Biomaterials. 2020 Jul;246:119999. doi: 10.1016/j.biomaterials.2020.119999. Epub 2020 Mar 28.
Abundant desmoplastic stroma, which typically exists in pancreatic ductal adenocarcinoma (PDAC), can act as a natural protective physical barrier rendering insufficient drug delivery and penetration. To address this issue, we herein report a two-step sequential delivery strategy for enhanced pancreatic cancer therapy. In this sequential strategy, the nitric oxide (NO) donor S-nitroso-N-acetylpenicillamine (SNAP) loaded liposomes (Lip-SNAP) were firstly delivered to pancreatic stellate cells (PSCs) in tumor tissue to inhibit the production of dense stroma, by inhibiting the expression of TGF-β1 and its downstream profibrotic signal transduction. Therefore, the PSC-mediated desmoplastic reaction could be suppressed by inhibiting the expression of fibronectin, α-SMA and collagen. The gemcitabine (GEM) loaded liposomes (Lip-GEM) were administrated subsequently. The enhanced intratumoral penetration of Lip-GEM was then achieved due to the stromal disruption in consequence of NO treatment, thus significantly improving the drug delivery efficiency. The tumor growth inhibition of the two-step sequential delivery of Lip-SNAP and Lip-GEM was investigated on both subcutaneous and orthotopic tumor mouse models, to show the remarkably improved therapeutic efficacy of GEM. Such NO-induced stromal depletion provides a general strategy to overcome the blockage of desmoplastic stroma on other therapeutic agents.
丰富的促结缔组织增生性基质通常存在于胰腺导管腺癌(PDAC)中,可作为一种天然的保护性物理屏障,导致药物递送和渗透不足。为了解决这个问题,我们在此报告一种用于增强胰腺癌治疗的两步序贯递送策略。在这种序贯策略中,首先将负载一氧化氮(NO)供体S-亚硝基-N-乙酰青霉胺(SNAP)的脂质体(Lip-SNAP)递送至肿瘤组织中的胰腺星状细胞(PSC),通过抑制转化生长因子-β1(TGF-β1)及其下游促纤维化信号转导来抑制致密基质的产生。因此,通过抑制纤连蛋白、α-平滑肌肌动蛋白(α-SMA)和胶原蛋白的表达,可以抑制PSC介导的促结缔组织增生反应。随后给予负载吉西他滨(GEM)的脂质体(Lip-GEM)。由于NO处理导致的基质破坏,Lip-GEM在肿瘤内的渗透得以增强,从而显著提高了药物递送效率。在皮下和原位肿瘤小鼠模型上研究了Lip-SNAP和Lip-GEM两步序贯递送对肿瘤生长的抑制作用,以显示GEM显著提高的治疗效果。这种由NO诱导的基质消耗提供了一种通用策略,以克服促结缔组织增生性基质对其他治疗药物的阻碍。